Group 1 - The controlling shareholder of Sanbai Shuo, Qingdao Haishuo Health Industry Development Co., Ltd., along with its concerted party Ningbo Hechuang Caizhi Investment Partnership, holds approximately 130 million shares, accounting for about 53.32% of the company's total share capital, and about 53.60% when excluding shares in the repurchase account [1] - Haishuo Development and Ningbo Hechuang plan to reduce their holdings by no more than approximately 7.27 million shares within three months after the announcement, representing about 2.98% of the total share capital and 3% when excluding shares in the repurchase account [1] Group 2 - Haili Biological's valuation has decreased by 50% over eight months, with its largest customer being a company that has not yet been established, indicating unusual circumstances surrounding the acquisition [1]
三柏硕：股东海硕发展、宁波和创计划减持公司股份合计不超过约727万股